114sek
1,6 %
Date:2024-05-03Time:14:20:32Latest report:Q4-2023List:First NorthTicker:ALZ
Market Cap:50 msekEnterprise Value:28 msekNet Sales:0,27 msekEarnings:-16,5 msekEmployees:0ISIN:SE0007413455

Ratios

10-year key figure history for Alzinova turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Alzinova with index and moving average MA50 and MA200.

Stockprice:1,14
MA50:1,84
MA200:2,63
Price/MA200:-57,2 %
RSI (14):21,8
Price/MA50:-38,7 %

Description

Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is also engaged in development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody. The product is in clinical development as a therapeutic vaccine for the treatment of Alzheimer’s.

Biotechnology